BioWorld

Sep. 18, 2009

Panel for Xenoport's RLS Drug Less Likely; Pain Data Positive

Investors where fired up Thursday after XenoPort Inc. reported top-line Phase IIb results showing that its gabapentin prodrug significantly reduced neuropathic pain associated with post-herpetic neuralgia (PHN) in adults, driving shares up 25.6 percent. (BioWorld Today) Read More

Seaside Shores up Funding with $30M Series B for Autism Work

In Biotech, Only One Certainty: Everything Is About to Change

Juvaris Gets $25M in Series B to Advance Add-on Flu Vaccine

Rigel Extends RA Drug Runway with $90M-Plus Share Offering

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

TL1A is overexpressed in hidradenitis suppurativa

BioWorld Science

Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...

IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa

BioWorld Science

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...

Illustration of head with maze that is missing parts

Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke

BioWorld Science

Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...

VST Bio’s VB-001 is neuroprotector after stroke

BioWorld Science

At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...